Beigene Ltd
ONC269.630USD
-6.899-2.50%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
26.72BMarket Cap
LossP/E TTM
More Details of Beigene Ltd Company
BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.
Company Info
Ticker SymbolONC
Company nameBeigene Ltd
IPO date- -
Founded at2010
CEOMr. John Victor Oyler
Number of employees11000
Security typeOrdinary Share
Fiscal year-end- -
Addressc/o Mourant Governance Services (Cayman)
CityGRAND CAYMAN
Stock exchangeThe Toronto Stock Exchange
CountryCayman Islands
Postal codeKY1-1108
Phone13459494123
Websitehttps://www.beigene.com/
Ticker SymbolONC
IPO date- -
Founded at2010
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
By RegionUSD
Name
Revenue
Proportion
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Shareholding Stats
Updated: Tue, Jun 3
Updated: Tue, Jun 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Shareholders
Shareholders
Proportion
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.70%
Corporation
17.31%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.86%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.68%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
559
66.79M
67.51%
+1.06M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
View more
Related ETFs
Updated: Mon, Jun 2
Updated: Mon, Jun 2
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.51%
Innovator IBD 50 Fund ETF
3.07%
Tema Oncology ETF
2.94%
Virtus LifeSci Biotech Products ETF
2.51%
VanEck Biotech ETF
2.23%
Global X Aging Population ETF
2.05%
iShares Health Innovation Active ETF
1.51%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.17%
ProShares Ultra Nasdaq Biotechnology
1.17%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.51%
Innovator IBD 50 Fund ETF
Proportion3.07%
Tema Oncology ETF
Proportion2.94%
Virtus LifeSci Biotech Products ETF
Proportion2.51%
VanEck Biotech ETF
Proportion2.23%
Global X Aging Population ETF
Proportion2.05%
iShares Health Innovation Active ETF
Proportion1.51%
iShares Biotechnology ETF
Proportion1.42%
Invesco Nasdaq Biotechnology ETF
Proportion1.17%
ProShares Ultra Nasdaq Biotechnology
Proportion1.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
